Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.09%||69.71||1.0%||$515.13m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.68%||206.61||1.9%||$454.10m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.98%||654.04||2.7%||$419.38m|
|SNSS||Sunesis Pharmaceuticals, Inc.||1.16%||4.36||0.7%||$304.78m|
|EXAS||EXACT Sciences Corp.||3.48%||86.26||18.0%||$150.95m|
|BMRN||BioMarin Pharmaceutical, Inc.||2.62%||88.38||4.2%||$138.75m|
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.